Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 4/20 | 0.48 |
| ▸ | BRAF | P15056 | 4/20 | 0.42 |
| ▸ | MAPK14 | Q16539 | 11/20 | 0.41 |
| ▸ | MAPK13 | O15264 | 7/20 | 0.41 |
| ▸ | MAPK12 | P53778 | 5/20 | 0.41 |
| ▸ | MAPK11 | Q15759 | 5/20 | 0.41 |
| ▸ | DDR2 | Q16832 | 1/20 | 0.39 |
| ▸ | FLT3 | P36888 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5056355 | 0.93 | MAPK14 (0.50) | NTRK1MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL5055029 | 0.92 | NTRK1 (0.51) | NTRK1BRAFMAPK14MAPK13MAPK12 | |
| SCHEMBL5054984 | 0.92 | NTRK1 (0.45) | NTRK1BRAFMAPK14MAPK13MAPK12 | |
| SCHEMBL5062229 | 0.90 | NTRK1 (0.44) | NTRK1BRAFMAPK14MAPK13MAPK12 | |
| SCHEMBL5052163 | 0.88 | NTRK1 (0.51) | NTRK1BRAFMAPK14MAPK13MAPK12 | |
| SCHEMBL5052162 | 0.88 | MAPK14 (0.38) | NTRK1BRAFMAPK14MAPK13MAPK12 | |
| SCHEMBL5054966 | 0.88 | MAPK14 (0.38) | NTRK1BRAFMAPK14MAPK13MAPK12 | |
| SCHEMBL5052268 | 0.88 | NTRK1 (0.38) | NTRK1BRAFMAPK14MAPK13MAPK12 | |
| SCHEMBL5059916 | 0.88 | NTRK1 (0.38) | NTRK1BRAFMAPK14MAPK13MAPK12 | |
| SCHEMBL5060021 | 0.87 | NTRK1 (0.39) | NTRK1MAPK14MAPK13MAPK12MAPK11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080113967-A1 | ENZYME MODULATORS AND TREATMENTS | DECIPHERA PHARMACEUTICALS, LLC (US) | 2008-05-15 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080113967-A1 | ENZYME MODULATORS AND TREATMENTS | ABL2, BRAF, MAP3K1 | NTRK1 217/4885BRAF 2/4885MAPK14 100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.